menu
    • menu
    [{"orgOrder":0,"company":"Cerebral Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Series B Financing","leadProduct":"Sodium Valproate","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cerebral Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Intracerebroventricular Implant","sponsorNew":"Cerebral Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Cerebral Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Cerebral Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sodium Valproate","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cerebral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Implant","sponsorNew":"Cerebral Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerebral Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cerebral Therapeutics","sponsor":"Lynx1 Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Series C Financing","leadProduct":"Sodium Valproate","moa":"Sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Cerebral Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Intracerebroventricular Implant","sponsorNew":"Cerebral Therapeutics \/ Lynx1 Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Cerebral Therapeutics \/ Lynx1 Capital Management"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Divalproex Sodium","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cereno Scientific \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cereno Scientific \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Sodium Valproate

    Menu

    Sodium Valproate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Cereno Scientific

    Sweden arrow
    Immuno-Oncology 360
    Not Confirmed

    Cereno Scientific

    Sweden arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Divalproex Sodium,Sodium Valproate

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Cereno's HDAC Inhibitor Reduces Risks from PAH in Phase 2 Trial

    Details : CS1 is an HDAC inhibitor that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for pulmonary arterial hypertension.

    Product Name : CS1

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    September 30, 2024

    Lead Product(s) : Divalproex Sodium,Sodium Valproate

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Cerebral Therapeutics

    U.S.A arrow
    Immuno-Oncology 360
    Not Confirmed

    Cerebral Therapeutics

    U.S.A arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sodium Valproate

    Therapeutic Area : Neurology

    Study Phase : Phase II

    Sponsor : Lynx1 Capital Management

    Deal Size : $40.0 million

    Deal Type : Series C Financing

    DEALS_DEV arrow-down

    Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing

    Details : The Company plans to use proceeds to complete an international Phase 2 double-blind, randomized, placebo-controlled clinical trial of its investigational drug Valproic Acid (CT-010) for the treatment of uncontrolled seizures in patients with medically re...

    Product Name : CT-010

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    June 28, 2022

    Lead Product(s) : Sodium Valproate

    Therapeutic Area : Neurology

    Highest Development Status : Phase II

    Sponsor : Lynx1 Capital Management

    Deal Size : $40.0 million

    Deal Type : Series C Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Cerebral Therapeutics

    U.S.A arrow
    Immuno-Oncology 360
    Not Confirmed

    Cerebral Therapeutics

    U.S.A arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sodium Valproate

    Therapeutic Area : Neurology

    Study Phase : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Cerebral Therapeutics Announces Enrollment of First Patient in a Multicenter Randomized Controlled Phase 2b Tr...

    Details : The Phase 2b, randomized, placebo-controlled, double-blind study is designed to expand on positive results of the ongoing Phase 1b/2a study assessing the safety and efficacy of intracerebroventricular administration of sodium valproate.

    Product Name : CT-010

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    November 17, 2020

    Lead Product(s) : Sodium Valproate

    Therapeutic Area : Neurology

    Highest Development Status : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Cerebral Therapeutics

    U.S.A arrow
    Immuno-Oncology 360
    Not Confirmed

    Cerebral Therapeutics

    U.S.A arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sodium Valproate

    Therapeutic Area : Neurology

    Study Phase : Phase II

    Sponsor : RA Capital Management

    Deal Size : $35.0 million

    Deal Type : Series B Financing

    DEALS_DEV arrow-down

    Cerebral Therapeutics Completes $35 Million Series B Financing

    Details : The funding will help the company to initiate Phase 2b clinical trial for the treatment of medically refractory epilepsy in 2020.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    January 07, 2020

    Lead Product(s) : Sodium Valproate

    Therapeutic Area : Neurology

    Highest Development Status : Phase II

    Sponsor : RA Capital Management

    Deal Size : $35.0 million

    Deal Type : Series B Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth